Human-computer collaboration for skin cancer recognition.

Journal: Nature medicine
Published Date:

Abstract

The rapid increase in telemedicine coupled with recent advances in diagnostic artificial intelligence (AI) create the imperative to consider the opportunities and risks of inserting AI-based support into new paradigms of care. Here we build on recent achievements in the accuracy of image-based AI for skin cancer diagnosis to address the effects of varied representations of AI-based support across different levels of clinical expertise and multiple clinical workflows. We find that good quality AI-based support of clinical decision-making improves diagnostic accuracy over that of either AI or physicians alone, and that the least experienced clinicians gain the most from AI-based support. We further find that AI-based multiclass probabilities outperformed content-based image retrieval (CBIR) representations of AI in the mobile technology environment, and AI-based support had utility in simulations of second opinions and of telemedicine triage. In addition to demonstrating the potential benefits associated with good quality AI in the hands of non-expert clinicians, we find that faulty AI can mislead the entire spectrum of clinicians, including experts. Lastly, we show that insights derived from AI class-activation maps can inform improvements in human diagnosis. Together, our approach and findings offer a framework for future studies across the spectrum of image-based diagnostics to improve human-computer collaboration in clinical practice.

Authors

  • Philipp Tschandl
    Department of Computing Science, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Christoph Rinner
    Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
  • Zoe Apalla
    Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Giuseppe Argenziano
    Dermatology Unit, University of Campania, Naples, Italy.
  • Noel Codella
    IBM TJ Watson Research Center, 1101 Kitchawan Rd, Yorktown Heights, NY, 10598, USA.
  • Allan Halpern
    Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Monika Janda
    Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Aimilios Lallas
  • Caterina Longo
    Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy; Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Centro Oncologico ad Alta Tecnologia Diagnostica-Dermatologia, Reggio Emilia, Italy.
  • Josep Malvehy
    Melanoma Unit, Dermatology Department, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Rarasd (CIBER ER), Instituto de Salud Carlos III, Barcelona, Spain.
  • John Paoli
  • Susana Puig
    Melanoma Unit, Dermatology Department, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Rarasd (CIBER ER), Instituto de Salud Carlos III, Barcelona, Spain.
  • Cliff Rosendahl
    School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • H Peter Soyer
    Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Brisbane, Australia.
  • Iris Zalaudek
  • Harald Kittler
    ViDIR Group, Department of Dermatology, Medical University of Vienna, Vienna, Austria. Electronic address: harald.kittler@meduniwien.at.at.